89938-53-4Relevant articles and documents
Cytotoxicity of new pyridazin-3(2H)-one derivatives orchestrating oxidative stress in human triple-negative breast cancer (MDA-MB-468)
Bouchmaa, Najat,Ben Mrid, Reda,Boukharsa, Youness,Nhiri, Mohamed,Ait Mouse, Hassan,Taoufik, Jamal,Ansar, M'hammed,Zyad, Abdelmajid
, (2018/11/02)
Triple-negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer characterized by high morbidity and mortality. In the absence of targeted therapy, only chemotherapy is available in this case of cancer. The current study investigated the antitumor effect of new pyridazin-3(2H)-one derivatives on the human TNBC cell line, MD-MB-468. The in vitro cytotoxic activities were investigated using the tetrazolium-based MTT assay. Lipid peroxidation, H2O2 content, and the specific activities of antioxidant enzymes were also determined. Two molecules, 6f and 7h, were found to be selectively highly active against tumor cells with IC50 values of 3.12 and 4.9 μM, respectively. Furthermore, cells exposed to 6f showed a significant increase in H2O2 and lipid peroxidation levels, accompanied by a decrease in the enzyme activities of glutathione reductase (GR) and thioredoxin reductase (TrxR). The cytotoxicity of the compound 6f may improve the therapeutic efficacy of the current treatment for TNBC via the inhibition of GR and TrxR activities.
The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates
Wang, Jane L.,Aston, Karl,Limburg, David,Ludwig, Cindy,Hallinan, Ann E.,Koszyk, Francis,Hamper, Bruce,Brown, David,Graneto, Matthew,Talley, John,Maziasz, Timothy,Masferrer, Jaime,Carter, Jeffery
scheme or table, p. 7164 - 7168 (2011/01/03)
In this manuscript, we report the discovery of the substituted 2-trifluoromethyl-2H-benzopyran-3-carboxylic acids as a novel series of potent and selective cyclooxygenase-2 (COX-2) inhibitors. We provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data. The challenge of a surprisingly long half-life (t 1/2 = 360 h) of the first clinical candidate 1 and human t 1/2 had been difficult to predict based on allometric scaling for this class of highly ppb compounds. We used a microdose strategy which led to the discovery of clinical agents 18c-(S), 29b-(S), and 34b-(S) with human half-life of 57, 13, and 11 h.
